<DOC>
	<DOCNO>NCT00966602</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety co-administration VX-770 VX-809 healthy adult .</brief_summary>
	<brief_title>Drug-Drug Interaction Study VX-809 VX-770 Healthy Subjects</brief_title>
	<detailed_description>Cystic fibrosis ( CF ) inherit disease result defect gene know cystic fibrosis transmembrane conductance regulator ( CFTR ) . CF affect approximately 70,000 child adult worldwide ( 30,000 United States ) common fatal genetic disease person European descent . Despite progress treatment CF antibiotic mucolytics , predict median age survival person CF mid-30s . Though disease affect multiple organ , morbidity mortality cause progressive loss lung function . This Phase 1 , randomize , double-blind , placebo-controlled , multiple-dose study orally administer VX-809 VX-770 healthy subject . The study evaluate safety tolerability co-administration VX-809 VX-770 healthy volunteer . Enrollment plan 24 subject 1 clinical site . Subjects randomize receive study drug placebo three 14-day treatment period separate 14-day washout period . In Treatment Period 1 , subject randomize study drug receive VX-809 every 24 hour . In Treatment Period 2 , subject randomize study drug receive VX-770 every 12 hour . In Treatment Period 3 , subject randomize study drug receive VX-809 every 24 hour VX-770 every 12 hour . Subjects randomize placebo receive placebo treatment period .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female subject 18 55 year age , inclusive Body mass index ( BMI ) 18.5 30.0 kg/m2 , inclusive Subjects childbearing potential sexually active must meet contraception requirement Female subject must negative serum pregnancy test screening , Day 1 , throughout study History illness , opinion investigator might confound result study pose additional risk administer study drug subject . This may include limited significant history cardiovascular , central nervous system , hepatobiliary renal disease , history mental illness Participated clinical study involve administration either investigational marketed drug within 60 day 7 terminal halflives ( whichever longer ) Screening visit Subject receive VX770 VX809 previous clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>